Answers are grounded in this paper and cite their sources.
Homeoboxes are the central nuclear effectors, adjacent to the oncogene, which propagate the transformed oncogenic state. We describe here activation of homeobox factor HOXA5 and the T-box factor TBX5 in response to growth factor restriction effected by the VEGF-A inhibitor bevacizumab (Avastin).
No takes yet. Share an insight, caveat, or question.
Shahan Mamoor (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: